Table 3 Utility scores split by patient type
Attribute | Level | Utility scores | ||
|---|---|---|---|---|
| Â | Â | Patients who had their first episode | Patients who had 2 to 5 episodes | Patients who had 6 or more episodes |
Side effects | Sedation | +241.8 | +235.4 | +219.5 |
| Â | Sexual side effects (prolactin) | +111.7 | +156.4 | +124.1 |
| Â | Weight gain of more than 7% of body mass | +93.7 | +136.1 | +105.9 |
| Â | Extrapyramidal side effect | +82.8 | +123.4 | +81.1 |
| Â | Metabolic side effects (diabetes, hypercholesterolaemia, dyslipidaemia) | +70.0 | +62.1 | +27.4 |
| Â | Tardive dyskinesia | 0 | 0 | 0 |
Pain at injection site | Absent | +173.8 | +169.1 | +194.3 |
| Â | Mild | +160.3 | +163.1 | +185.8 |
| Â | Moderate | +130.2 | +107.7 | +145.7 |
| Â | Severe | 0 | 0 | 0 |
Risk of embarrassment and potential harm to therapeutic relationship | Low risk | +139.7 | +120.0 | +121.4 |
| Â | High risk | 0 | 0 | 0 |
Routes of administration | Buttock muscle (gluteal) | +67.0 | +32.0 | +74.4 |
| Â | Deltoid muscle | +54.2 | +29.3 | +54.1 |
| Â | Ventro gluteal | 0 | 0 | 0 |